BioNTech SE (BNTX) AI Stock Analysis

• Market Cap: $25.12B
• Dividend Yield: N/A
• Average Volume (3M): 1.12M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: 7.51%
• EPS Growth: 30.53%
• Country: US
• Employees: 6,772
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.88
• Shares Outstanding: 240,398,730
• 10 Day Avg. Volume: 826,964
• 30 Day Avg. Volume: 1,122,596
• PEG Ratio: 0.23
• Price to Book (P/B): 1.36
• Price to Sales (P/S): 9.62
• P/FCF Ratio: -108.15
• Enterprise Value/Market Cap: 0.39
• Enterprise Value/Revenue: 3.43
• Enterprise Value/Gross Profit: 4.30
• Enterprise Value/Ebitda: -43.41
• 1Y Price Target: $134.07
• Price Target Upside: 27.09% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 16

• Rating: 56 Neutral
• Price Target: $109.00 ▲(3.33% Upside)

BioNTech's overall stock score is driven by its mixed financial performance and valuation concerns, offset by positive earnings call sentiment and strategic collaborations. The strong balance sheet provides some stability, but profitability and cash flow challenges remain significant risks.

Positive Factors

Strategic Collaborations

The collaboration with Bristol-Myers Squibb provides BioNTech with significant financial benefits and strengthens its oncology market position, enhancing its long-term growth prospects.

Strong Financial Position

A robust cash position provides BioNTech with the flexibility to invest in R&D and strategic initiatives, supporting long-term growth and operational stability.

Advancements in Oncology Pipeline

Progress in the oncology pipeline, particularly in lung cancer, positions BioNTech to capture market share in a high-demand therapeutic area, supporting sustainable growth.

Negative Factors

Profitability Challenges

Negative net profit margins reflect operational inefficiencies and profitability challenges, which could hinder BioNTech's ability to reinvest in growth and innovation.

Cash Flow Challenges

Negative cash flow indicates potential liquidity issues, limiting BioNTech's ability to fund operations and strategic initiatives without external financing.

COVID-19 Vaccine Market Challenges

Decreased demand for COVID-19 vaccines could lead to reduced revenue, impacting BioNTech's financial performance and necessitating a shift in strategic focus.

BioNTech SE Business Overview & Revenue Model

Company Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

How the Company Makes Money

BioNTech generates revenue primarily through the commercialization of its products, particularly its COVID-19 vaccine, which has been a significant source of income due to global demand and government contracts. The company has established key partnerships, notably with Pfizer, which has enabled it to scale production and distribution effectively. In addition to vaccine sales, BioNTech is also involved in research collaborations and licensing agreements, allowing it to earn milestone payments and royalties from its developed therapies. The diversification of its product pipeline, including cancer therapies and other mRNA-based treatments, further contributes to its revenue stream by targeting various therapeutic areas and expanding its market reach.

BioNTech SE Financial Statement Overview

Summary

BioNTech SE shows a mixed financial performance. While revenue has grown slightly, profitability is a concern with negative net profit margins and cash flow challenges. The balance sheet is strong with low leverage, but operational inefficiencies need addressing.

Income Statement

BioNTech SE's income statement shows a mixed performance. The company experienced a slight revenue growth of 4.79% in the TTM period, but it is coming off a significant decline from previous years. Gross profit margins remain strong at 79.35%, but net profit margins have turned negative, indicating profitability challenges. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Overall, while revenue is growing, profitability is a concern.

Balance Sheet

The balance sheet of BioNTech SE is relatively strong with a low debt-to-equity ratio of 0.015, indicating low leverage and financial stability. However, the return on equity is negative, reflecting recent losses. The equity ratio is healthy, suggesting a solid capital structure. Despite recent profitability issues, the company's balance sheet remains robust.

Cash Flow

Cash flow analysis reveals challenges for BioNTech SE. The operating cash flow is negative, and free cash flow has significantly deteriorated, although it shows a high free cash flow to net income ratio due to negative net income. The company needs to improve its cash generation capabilities to support operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.88B	2.75B	3.82B	17.31B	18.98B	482.32M
Gross Profit	2.30B	2.21B	3.22B	12.78B	15.12B	-222.04M
EBITDA	-227.60M	-367.10M	1.09B	12.86B	15.73B	-97.89M
Net Income	-347.44M	-665.30M	930.30M	9.43B	10.29B	15.20M
Balance Sheet
Total Assets	21.64B	22.53B	23.01B	23.28B	15.83B	2.32B
Cash, Cash Equivalents and Short-Term Investments	14.04B	16.78B	16.55B	14.06B	2.07B	1.35B
Total Debt	269.60M	254.20M	219.10M	212.20M	301.50M	240.19M
Total Liabilities	3.13B	3.12B	2.76B	3.22B	3.94B	946.77M
Stockholders Equity	18.51B	19.41B	20.25B	20.06B	11.89B	1.37B
Cash Flow
Free Cash Flow	-2.54B	-244.60M	4.67B	13.21B	735.70M	-98.92M
Operating Cash Flow	-1.72B	207.70M	5.37B	13.58B	889.70M	-13.47M
Investing Cash Flow	1.69B	-2.08B	-6.95B	-35.30M	-566.10M	-144.85M
Financing Cash Flow	-42.30M	-45.90M	-778.60M	-1.42B	94.20M	894.73M

BioNTech SE Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 105.49
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTX, the sentiment is Positive. The current price of 105.49 is above the 20-day moving average (MA) of 99.82, above the 50-day MA of 105.29, and below the 200-day MA of 106.92, indicating a neutral trend. The MACD of -0.69 indicates Negative momentum. The RSI at 58.05 is Neutral, neither overbought nor oversold. The STOCH value of 92.60 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BNTX.

BioNTech SE Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMAB	82 Outperform	$19.20B	15.91	26.08%	―	23.25%	64.46%
ARGX	74 Outperform	$49.04B	37.58	24.75%	―	89.58%	―
SWTX	61 Neutral	―	―	―	―	730.42%	31.63%
ALNY	60 Neutral	$60.43B	―	-257.82%	―	5.01%	-330.09%
BNTX	56 Neutral	$25.12B	―	-1.81%	―	7.51%	30.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MRNA	47 Neutral	$11.04B	―	-27.50%	―	-38.95%	51.07%

BioNTech SE Corporate Events

BioNTech and BMS Reveal Promising Phase 2 Results for Lung Cancer Treatment

On September 8, 2025, BioNTech SE and Bristol Myers Squibb presented interim data from a Phase 2 trial evaluating pumitamig, a bispecific antibody, in patients with extensive-stage small cell lung cancer. The data showed promising antitumor activity, with a 76.3% confirmed objective response rate and a 100% disease control rate, suggesting potential for pumitamig to become a new standard of care in this aggressive cancer type. The trial’s results are being used to inform a global Phase 3 trial, and pumitamig has received Orphan Drug designation from the FDA.

BioNTech and Bristol-Myers Squibb Partner to Advance Cancer Therapy

On June 2, 2025, BioNTech SE entered into a Global Co-Development and Co-Commercialization Agreement with Bristol-Myers Squibb Company to develop, manufacture, and commercialize the bispecific antibody BNT327 for various solid tumor types. The agreement, which was amended on August 15, 2025, includes a $1.5 billion upfront payment to BioNTech and up to $7.6 billion in additional milestone payments. The collaboration will see both companies sharing profits and losses equally, with a focus on maximizing the success and efficiency of BNT327’s development and commercialization. This strategic partnership is expected to enhance BioNTech’s position in the oncology market and provide significant financial benefits.

BioNTech and DualityBio’s Phase 3 Trial Success in Breast Cancer

On September 5, 2025, BioNTech SE and Duality Biologics announced that their Phase 3 trial in China for trastuzumab pamirtecan (BNT323/DB-1303) met its primary endpoint of progression-free survival in patients with HER2-positive metastatic breast cancer. This milestone marks the first positive Phase 3 data from their strategic collaboration, highlighting the potential of trastuzumab pamirtecan as a new treatment option. The success of this trial strengthens BioNTech’s position in oncology and supports further development of the drug in other regions, including the U.S. and EU.

FDA Approves BioNTech and Pfizer’s New COVID-19 Vaccine for High-Risk Groups

On August 27, 2025, BioNTech SE and Pfizer Inc. announced that the U.S. Food and Drug Administration approved their LP.8.1-adapted monovalent COVID-19 vaccine, COMIRNATY® LP.8.1, for adults aged 65 and older, and individuals aged 5 through 64 with underlying conditions at high risk for severe COVID-19 outcomes. This approval is based on extensive clinical and real-world data demonstrating the vaccine’s safety and efficacy. The vaccine targets the SARS-CoV-2 sublineage LP.8.1, aligning with FDA guidance to address circulating strains. Shipping of the vaccine will commence immediately to ensure availability in pharmacies, hospitals, and clinics across the U.S., reinforcing BioNTech’s and Pfizer’s positions in the vaccine market and their commitment to addressing public health needs.

BioNTech Settles Patent Disputes with CureVac and GSK

On August 7, 2025, BioNTech SE, along with its partners Pfizer and CureVac, reached a settlement to resolve ongoing patent litigation related to COVID-19 vaccines in the United States. The agreement includes dismissing existing claims and granting BioNTech a non-exclusive license for mRNA-based vaccines in the U.S. and worldwide, contingent on the acquisition of CureVac. The settlement involves significant financial transactions, including payments to GSK and CureVac, and sets a framework for resolving international disputes, impacting BioNTech’s operational and strategic positioning in the vaccine market.

BioNTech SE Reports Strong Financial Results for Mid-2025

On August 4, 2025, BioNTech SE released its financial results for the three and six months ending June 30, 2025. The company reported increased revenues compared to the previous year, reflecting its ongoing efforts in research and development. This financial update highlights BioNTech’s strong market position and its commitment to advancing its product pipeline, which is crucial for stakeholders and investors.

BioNTech Reports Q2 2025 Financials and Strategic Collaborations

On August 4, 2025, BioNTech SE announced its financial results for the second quarter of 2025, reporting revenues of €260.8 million and a net loss of €386.6 million. The company highlighted significant strategic moves, including a collaboration with Bristol Myers Squibb to advance its BNT327 antibody candidate and the acquisition of CureVac to enhance its mRNA capabilities. These developments are expected to strengthen BioNTech’s financial position and expand its oncology strategy. The company also received approval for a new variant-adapted COVID-19 vaccine from the European Commission, with preparations for its launch underway.

BioNTech and Pfizer’s New COVID-19 Vaccine Awaits EU Approval

On July 25, 2025, BioNTech SE and Pfizer Inc. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended marketing authorization for their LP.8.1-adapted COVID-19 vaccine, COMIRNATY® LP.8.1. This vaccine is designed for individuals aged 6 months and older to prevent COVID-19 caused by SARS-CoV-2. The recommendation is based on data showing improved immune responses against current and emerging variants compared to previous formulations. The European Commission’s decision is pending, and the companies have already started manufacturing to ensure readiness for the upcoming vaccination season. This development is expected to strengthen BioNTech’s position in the vaccine market and address the evolving needs of COVID-19 immunization.

BioNTech Announces Departure of Chief Strategy Officer Ryan Richardson

On July 17, 2025, BioNTech SE announced that Ryan Richardson will step down as Chief Strategy Officer on September 30, 2025, to pursue new professional opportunities. During his tenure, Richardson significantly contributed to BioNTech’s growth, including its Series B financing, IPO, and subsequent equity financings, raising over USD 1 billion. He played a crucial role in BioNTech’s transition from a private clinical-stage biotech to a publicly listed company, helping expand its global shareholder base and strategic collaborations. His departure marks a pivotal moment as BioNTech aims to become a multi-product company, continuing its mission to innovate and bring new therapies to cancer patients.

BioNTech SE Updates Articles of Association to Boost Financial Flexibility

On May 30, 2025, BioNTech SE registered its updated Articles of Association with the local court in Mainz, Germany. This update includes provisions for a potential increase in share capital up to EUR 124,276,100 through the issuance of new shares, with specific conditions under which shareholder subscription rights can be excluded. This strategic move is designed to enhance BioNTech’s financial flexibility and support its growth initiatives, potentially impacting its market position and shareholder value.

BioNTech SE Announces Acquisition of CureVac N.V.

On June 12, 2025, BioNTech SE announced a purchase agreement to acquire CureVac N.V. through a public exchange offer, followed by a reorganization to make CureVac a wholly-owned subsidiary. This strategic acquisition aims to consolidate BioNTech’s position in the biotechnology sector by expanding its capabilities and resources, potentially impacting stakeholders by enhancing the company’s market share and operational efficiencies.